<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758523</url>
  </required_header>
  <id_info>
    <org_study_id>13-056-2</org_study_id>
    <secondary_id>2P60AA003510</secondary_id>
    <nct_id>NCT01758523</nct_id>
  </id_info>
  <brief_title>Dutasteride Treatment for the Reduction of Heavy Drinking in Men</brief_title>
  <official_title>Dutasteride Treatment for the Reduction of Heavy Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and potential benefit of the medication dutasteride to
      help men reduce or stop drinking alcohol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extensive preclinical studies indicate that neuroactive steroids medicate important effects
      of alcohol and support the examination of neuroactive steroid modulators as treatment options
      for alcohol use problems. Dutasteride, a widely prescribed medication for benign prostatic
      hypertrophy, blocks a key step in the production of neuroactive steroids and represents a
      promising candidate for treatment of alcohol use disorders. This study will use a 12-week
      randomized placebo controlled design to examine the safety and efficacy of dutasteride to
      reduce drinking among a sample of 160 men with hazardous levels of alcohol use. It will
      additionally examine the potential moderation of dutasteride treatment effects by a common
      missense polymorphism in a neuroactive steroid biosynthetic enzyme that we have previously
      reported to be associated with alcohol dependence. Identification of genetic predictors of
      medication response offers the potential for matching alcohol treatment medications with
      those most likely to respond.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heavy Drinking Days Per Week</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Number of days / study week with 5 or more drinks consumed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinks Per Week</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Total number of drinks aggregated by week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With no Heavy Drinking Days</measure>
    <time_frame>Last 4 weeks of treatment</time_frame>
    <description>Number of participants with no heavy drinking days (days with 5 or more drinks) during the last 4 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With no Hazardous Drinking</measure>
    <time_frame>Last 4 weeks of treatment</time_frame>
    <description>Number of participants with no hazardous drinking (not more than 4 drinks on one day and not more than 14 drinks per week) during the last 4 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDD/ Week by Treatment Group and AKR1C3*2 Genotype</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Change in Number of days / week with 5 or more drinks consumed contrasting AKR1C3*2 CC vs. G-carrier genotype and treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate-deficient Transferrin</measure>
    <time_frame>end of 12-week treatment vs. baseline</time_frame>
    <description>Carbohydrate-deficient transferrin (CDT) at end of treatment as percentage of baseline. Serum CDT is a biochemical measure of heavy alcohol use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <arm_group_label>dutasteride</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  an average weekly ethanol consumption of at least 24 standard drinks;

          -  be able to read English at the 8th grade or higher level;

          -  no evidence of significant cognitive impairment;

          -  be willing to provide signed, informed consent to participate in the study (including
             a willingness to stop or reduce drinking to non-hazardous levels);

          -  be willing to nominate an individual who will know the patient's whereabouts to
             facilitate follow up during the study

        Exclusion Criteria:

          -  history of significant alcohol withdrawal symptoms (e.g. substantial tremor, autonomic
             changes, perceptual distortions, seizures, delirium, or hallucinations);

          -  current Diagnostic and Statistical Manual Version IV (DSM-IV) diagnosis of Alcohol
             Dependence who on clinical examination by a physician, are deemed to be too severely
             alcohol dependent to permit them to participate in a placebo-controlled study (e.g.
             evidence of serious adverse medical or psychiatric effects that are exacerbated by
             heavy drinking and would, for safety reasons, lead the physician to urge the patient
             to be totally abstinent and engage in an empirically supported treatment).

          -  current, clinically significant physical disease or abnormality on the basis of
             medical history, physical examination, or routine laboratory evaluation,(we will not
             exclude patients with hypertension, diabetes mellitus, asthma or other common medical
             conditions, if these are adequately controlled and the patient has an ongoing
             relationship with a primary care provider)

          -  serious psychiatric illness on the basis of history or psychiatric examination (i.e.,
             schizophrenia, bipolar disorder, severe or psychotic major depression, organic mental
             disorder, current clinically significant eating disorder, or substantial suicide or
             violence risk);

          -  current DSM-IV diagnosis of drug dependence (other than nicotine dependence);

          -  currently taking psychotropics other than medication for depression/anxiety disorder
             (with stable dose for at least 4 weeks),medications for treatment of Attention
             Deficit/Hyperactivity Disorder (with stable dose for at least 4 weeks), a
             non-benzodiazepine sleep medication or a low dose of benzodiazepine equivalent to 2 mg
             clonazepam or lorazepam per day;

          -  are considered by the investigators to be an unsuitable candidate for receipt of an
             investigational drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Covault, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 24, 2012</study_first_submitted>
  <study_first_submitted_qc>December 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <results_first_submitted>February 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Jonathan Covault</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>neuroactive steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT01758523/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>47 subjects not randomized: 23 excluded at in person screening visit; 24 subjects withdrew prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dutasteride</title>
          <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended &gt;/= 1 Visit Post-randomization</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who completed at least 1 visit post-randomization (modified intention to treat sample)</population>
      <group_list>
        <group group_id="B1">
          <title>Dutasteride</title>
          <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" spread="7.9"/>
                    <measurement group_id="B2" value="53.1" spread="9.4"/>
                    <measurement group_id="B3" value="53.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heavy Drinking Days (HDD)/wk</title>
          <description>days/week with 5 or more drinks over the 60 days prior to screening visit</description>
          <units>heavy drinking days / week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="2.2"/>
                    <measurement group_id="B2" value="5.2" spread="2.1"/>
                    <measurement group_id="B3" value="5.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks/week</title>
          <description>Total standard drinks / week over 60 day prior to screening visit</description>
          <units>drinks/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="24"/>
                    <measurement group_id="B2" value="47.3" spread="20.4"/>
                    <measurement group_id="B3" value="48.0" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AbstinentDays/week</title>
          <description>Days per week with no drinking during the 60 days prior to screening visit</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.67" spread="1.1"/>
                    <measurement group_id="B2" value="0.62" spread="1.1"/>
                    <measurement group_id="B3" value="0.64" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DSM-IV Alcohol Dependence criteria</title>
          <description>Number of current Diagnostic and Statistical Manual (DSM-IV) criteria for alcohol dependence (0-7; higher number greater severity of dependence; &gt;2 criteria required for diagnosis of alcohol dependence)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="1.6"/>
                    <measurement group_id="B2" value="4.0" spread="1.6"/>
                    <measurement group_id="B3" value="4.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Inventory of Problems</title>
          <description>The Short Inventory of Problems (SIP). The SIP, is a 15-item instrument with a total score that ranges from 0 to 45, higher score worse outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.2" spread="8.2"/>
                    <measurement group_id="B2" value="16.8" spread="8.8"/>
                    <measurement group_id="B3" value="17.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoker</title>
          <description>5 or more cigarettes per day</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heavy Drinking Days Per Week</title>
        <description>Number of days / study week with 5 or more drinks consumed</description>
        <time_frame>12-week treatment period</time_frame>
        <population>Modified Intention to Treat (ITT) all subjects who attended one or more post-randomization visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride</title>
            <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Heavy Drinking Days Per Week</title>
          <description>Number of days / study week with 5 or more drinks consumed</description>
          <population>Modified Intention to Treat (ITT) all subjects who attended one or more post-randomization visit.</population>
          <units>heavy drinking days/week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.33"/>
                    <measurement group_id="O2" value="2.67" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drinks Per Week</title>
        <description>Total number of drinks aggregated by week</description>
        <time_frame>12-week treatment period</time_frame>
        <population>Modified ITT (all subjects who attended one or more post-randomization visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride</title>
            <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Drinks Per Week</title>
          <description>Total number of drinks aggregated by week</description>
          <population>Modified ITT (all subjects who attended one or more post-randomization visit)</population>
          <units>drinks/week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="2.6"/>
                    <measurement group_id="O2" value="27.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With no Heavy Drinking Days</title>
        <description>Number of participants with no heavy drinking days (days with 5 or more drinks) during the last 4 weeks of treatment.</description>
        <time_frame>Last 4 weeks of treatment</time_frame>
        <population>Per protocol 12-week completer</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride</title>
            <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Heavy Drinking Days</title>
          <description>Number of participants with no heavy drinking days (days with 5 or more drinks) during the last 4 weeks of treatment.</description>
          <population>Per protocol 12-week completer</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>6.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With no Hazardous Drinking</title>
        <description>Number of participants with no hazardous drinking (not more than 4 drinks on one day and not more than 14 drinks per week) during the last 4 weeks of treatment.</description>
        <time_frame>Last 4 weeks of treatment</time_frame>
        <population>Per protocol 12 week treatment completers</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride</title>
            <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Hazardous Drinking</title>
          <description>Number of participants with no hazardous drinking (not more than 4 drinks on one day and not more than 14 drinks per week) during the last 4 weeks of treatment.</description>
          <population>Per protocol 12 week treatment completers</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>20.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDD/ Week by Treatment Group and AKR1C3*2 Genotype</title>
        <description>Change in Number of days / week with 5 or more drinks consumed contrasting AKR1C3*2 CC vs. G-carrier genotype and treatment group</description>
        <time_frame>12-week treatment period</time_frame>
        <population>Modified ITT (all subjects who attended one or more post-randomization visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride - AKR1C3*2 CC</title>
            <description>dutasteride treated AKR1C3*2 CC genotype subjects</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill - AKR1C3*2 CC</title>
            <description>placebo treated AKR1C3*2 CC genotype subjects</description>
          </group>
          <group group_id="O3">
            <title>Dutasteride - AKR1C3*2 G-carrier</title>
            <description>dutasteride treated AKR1C3*2 G-carrier genotype subjects</description>
          </group>
          <group group_id="O4">
            <title>Sugar Pill - AKR1C3*2 G-carrier</title>
            <description>placebo treated AKR1C3*2 G-carrier genotype subjects</description>
          </group>
        </group_list>
        <measure>
          <title>HDD/ Week by Treatment Group and AKR1C3*2 Genotype</title>
          <description>Change in Number of days / week with 5 or more drinks consumed contrasting AKR1C3*2 CC vs. G-carrier genotype and treatment group</description>
          <population>Modified ITT (all subjects who attended one or more post-randomization visit)</population>
          <units>heavy drinking days/week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.48"/>
                    <measurement group_id="O2" value="2.9" spread="0.53"/>
                    <measurement group_id="O3" value="2.05" spread="0.42"/>
                    <measurement group_id="O4" value="2.5" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <p_value_desc>significance for drug x AKR1C3*2 G-carrier genotype</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbohydrate-deficient Transferrin</title>
        <description>Carbohydrate-deficient transferrin (CDT) at end of treatment as percentage of baseline. Serum CDT is a biochemical measure of heavy alcohol use.</description>
        <time_frame>end of 12-week treatment vs. baseline</time_frame>
        <population>Per protocol 12-week completers (serum sample not available for 1 placebo subject).</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride</title>
            <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Carbohydrate-deficient Transferrin</title>
          <description>Carbohydrate-deficient transferrin (CDT) at end of treatment as percentage of baseline. Serum CDT is a biochemical measure of heavy alcohol use.</description>
          <population>Per protocol 12-week completers (serum sample not available for 1 placebo subject).</population>
          <units>percentage of baseline CDT</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="3.8"/>
                    <measurement group_id="O2" value="107" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Bi-weekly during 12-week active treatment then bi-monthly for 6 months</time_frame>
      <desc>At each patient visit the study nurse used a 16-item adverse events questionnaire to screen for presence of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dutasteride</title>
          <description>4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
Dutasteride</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
sugar pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsillar abscess</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>alcohol withdrawal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle or joint pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reduced Libido</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Impotence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jonathan Covault</name_or_title>
      <organization>University of Connecticut School of Medicine</organization>
      <phone>860-679-7560</phone>
      <email>jocovault@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

